Clinical Trial Detail

NCT ID NCT02362035
Title ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

hematologic cancer

Therapies

Acalabrutinib

Pembrolizumab

Age Groups: adult

No variant requirements are available.